Despite the scientific research on Gerovital, American health professionals generally have viewed Dr. Aslan with scepticism. The allopathic orientation of medicine favours creating conditions in the body, which are incompatible with the disease. Dr Aslan`s approach more aptly could be termed homeopathic. It aims to restore balance by mobilising the body's existing defences. The allopathic approach places less emphasis on preventative treatment. It also raises suspicion about products claiming to have diverse benefits. The first American response to the Romanian reports was not long in coming. An article negative to procaine therapy appeared in the Journal of the American Medical Association. This piece discussed several investigations by both English and American scientists. These research projects asserted that "GH3 was harmless but that it did little or no good. (6)

These conclusions differed vastly from those originating in Europe. A research team from the Chicago Medical School Institute for Medical research sought to resolve the conflicts in 1965. It concluded that the American and English investigators did not employ the Romanian formulation. They instead used a form of unstabilised procaine. Further, the results obtained with Dr. Aslan`s product during the Chicago study were the same as she had claimed. (7). However only the negative articles continued to receive wide attention. More than 200 positive reports existing at that time never reached the major medical journals. (8)

From this point on, G.H.3 fell into relative obscurity. Part of the problem was non-availability of the genuine formulation. Only a few foreign clinics could acquire it. This meant high costs for G.H.3 users. The rich and famous went on yearly pilgrimages to Romania.

Various researchers sought and failed to obtain FDA approval for Gerovital as a drug (A Dr Sapse working as an intern for Dr Aslan did obtain FDA permission to test G.H3 with a view to marketing GH3 as an anti depressant for the elderly. Unfortunately after passing Phase One trials proving its safety wild media editorial flights of fancy within the media at that time persuaded the FDA to change the rules for phase two and three and his company was made bankrupt). Then as now the pharmaceutical market was geared for patent products. The money needed to satisfy standard protocols was not available for an unpatentable product such as G.H.3. The contention that as a nutrient G.H.3 has never needed such approval will be detailed later but it is also worth mentioning here that G.H3 was accepted as a provitamin food in the USA in 1994 and as "non-medicine by function" at least before 1994 in the UK.. However, the mire of prevailing circumstances insured that Gerovital H3 generally would not be available outside Romania.

With changing awareness about nutrition and preventative health care, G.H.3 gradually has became more recognised. However, we need first develop a picture of its possible actions and benefits.